Shamburg News · 8-K filed Nov 16, 2026, 8:37 AM EST

Rein Therapeutics Reports Preliminary Blinded Phase 2 RENEW Data and Q3 2026 Financial Results

RNTX · Rein Therapeutics, Inc.

  • Other event
  • Earnings
  • Financial statements
  • Materiality: high

Rein Therapeutics announced preliminary blinded twelve-week observations from its ongoing Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis, reporting that 33% of evaluable patients (8 of 24) showed FVC improvement from baseline. The company also reported third quarter 2026 results, including a net loss of $5.5 million and cash, cash equivalents and marketable securities of $36.5 million as of September 30, 2026. Rein stated that the trial remains blinded, that the findings do not establish a treatment effect, and that topline data are expected in 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-462261.

Written from the filing by Shamburg Markets. Figures are as reported by the company.